Are measurements of LDL particles ready for prime time?

Clinical Chemistry

Volumn 52, Issue 9, 2006, Pages 1643-1644

  Stein, Evan A ^a  

^a Medpace Reference Laboratories ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANALYTIC METHOD; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD SAMPLING; CALIBRATION; CARDIOVASCULAR DISEASE; CLINICAL LABORATORY; CORONARY ARTERY DISEASE; CORONARY RISK; DENSITY GRADIENT CENTRIFUGATION; EDITORIAL; GEL ELECTROPHORESIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; TUBE GEL ELECTROPHORESIS;

CENTRIFUGATION, DENSITY GRADIENT; CHOLESTEROL, LDL; CLINICAL CHEMISTRY TESTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MULTICENTER STUDIES; PARTICLE SIZE;

EID: 33748306042     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.073452     Document Type: Editorial

References (12)

1. Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin. Chem. 2006;52:1722-7.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
4. The Working Group on Lipoprotein Measurement, Bachorik PS, Myers GL, Ross JW, and Stein EA, Recommendations on Lipoprotein Measurement. Bethesda: National Institutes of Health-National Heart, Lung and Blood Institute, 1995: NIH Pub #95-3044.
5. Stein EA. Are LDL subclass measurements clinically relevant? Nature: Clinical Practice Endocrinology & Metabolism. 2006;2:120-1.
6. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins. The Lancet 2005;366:1267-78.
7. Crouse JR, Parks JS, Schey HM, et al. Studies of low-density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 1985;26:566-74.
8. Grundy SM. Low-density lipoprotein, Non-high-density lipoprotein, and apolipoprotein B as targets of lipid lowering therapy. Circulation 2002;106:2526-9.
9. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. The Lancet 2001;358:2026-33.
10. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 2004;364:937-52.
11. Gotto A, Whitney E, Stein E, Shapiro D, Clearfield M, Weis Stephen, et al. Relation between relation and on-treatment lipid parameters and first accurate major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.
12. Anonymous (online August 3, 2005). LabCorp® to offer LipoScience's NMR lipoprofile test. [http://www.liposcience.com/control.cfm?id=54&prid=40]